In this issue:
Herbicide picloram linked to early-onset CRC
Time of day immunotherapy administration: controversy continues
Could GLP-1 agonists improve survival in breast cancer patients?
Transanal TME safe and reduces conversion rates in mid and low rectal cancer
Efficacy maintained without pre-op carboplatin in early HER2+ breast cancer
Tucatinib combo maintenance prolongs PFS in HER2+ metastatic breast cancer
Amivantamab active in chemorefractory RAS/BRAF wild-type metastatic CRC
Neoadjuvant pembrolizumab does not adversely impact surgical outcomes in TNBC
Predictors of VCF post-SBRT in potentially unstable spinal metastases
Intravenous analgesia regimens outperform oral opioids for severe cancer pain
Please login below to download this issue (PDF)